MicroStockHub/iStock via Getty Images Investment Overview - Background To Recent Explosive Share Price Growth Foster City, California based Vaxcyte (NASDAQ:PCVX) completed its Initial Public Offering (IPO) in June 2020, raising $287.5m via the issuance of ~18m shares priced at $16 per share. At the time, the company discussed its business as follows: Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed t ...

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinicalstage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sol ...

Shares of Vaxcyte (PCVX) rose more than 36% on Tuesday after it reported positive top-line results from a phase I/II study on VAX-31, which is an investigational 31-valent pneumococcal conjugate vaccine (PCV). The study was conducted on adults aged 50 years and older. Data from the study showed that the study participants who received VAX-31 achieved 'robust' immune responses for all 31 serotypes across all three dose levels (low, medium and high) in a six-month evaluation period. While the vaccine met or e ...

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinicalstage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30 ...

Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older. Competitors Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) are moving lower amid those headlines, however. Below, let's dig into how these stocks have fared on the charts lately. PCVX was last seen up 38.7% to trade at $111.98, and earlier notched a fresh all-time high of $119.27. The equity found re ...

-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes -- -- At All Doses Studied, VAX-31 Was Observed to be Well Tolerated and Demonstrated a Safety Profile Similar to Prevnar 20® -- -- Topline Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver BroadestSpectrum Pneumococcal Conjugate Vaccine Candidates th ...

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinicalstage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vacc ...

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vaxcyte, Inc. (NASDAQ: PCVX) on behalf of the company's shareholders. The investigation seeks to determine whether Vaxcyte's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Vaxcyte, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/vaxcyte-inc/ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 10-Q ___________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------|---- ...

Exhibit 99.1 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1. ...